Trials / Completed
CompletedNCT05483257
Molecular Subtyping for Prognosis Evaluation in Resected Pancreatic Adenocarcinoma
Molecular Subtyping Based on Specific HLA-I Genotypes for Prognosis Evaluation in Resected Pancreatic Adenocarcinoma: A Retrospective Observational Cohort Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 226 (actual)
- Sponsor
- BAIYONG SHEN · Academic / Other
- Sex
- All
- Age
- 34 Years – 84 Years
- Healthy volunteers
- Not accepted
Summary
Pancreatic adenocarcinoma (PAAD) patients following surgeries are prone to relapse shortly, while it is not well understood by current biomarkers. Given the potential associations of human leukocyte antigen class I (HLA-I) genotype with oncogenic mutational profile and immunotherapy efficacy, we aimed to assess whether differential HLA-I genotype could predict the postoperative outcomes in resected PAAD patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Multigene panel for next-generation sequencing | HLA-I genotyping based on next-generation sequencing for prognosis evaluation |
Timeline
- Start date
- 2018-03-14
- Primary completion
- 2020-08-03
- Completion
- 2021-09-13
- First posted
- 2022-08-02
- Last updated
- 2022-08-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05483257. Inclusion in this directory is not an endorsement.